BIOMAT Database Logo BIOMAT Database Logo

End-stage renal disease in patients with rheumatoid arthritis. 2017

Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Division of Rheumatology, University of South Carolina School of Medicine, 2 Medical Park, Columbia, SC 29203. Electronic address: sunita.paudyal@uscmed.sc.edu.

To determine the frequency of end-stage renal disease (ESRD) in patients with rheumatoid arthritis (RA), the causes of ESRD, and the treatment of RA in the setting of ESRD. Cross-sectional study of RA (N = 3754) and non-RA (N = 326,776) patients in the United States Renal Data System (USRDS) during 2011 (N = 330,530). The epidemiology of ESRD in RA was determined and the etiology of ESRD in patients with and without RA was compared. The frequency of patients with RA with at least one filled prescription for prednisone/prednisolone, a DMARD, and/or a biologic in 2011 was determined. The prevalence of RA with ESRD in the USRDS in 2011 was 1.1%. There were significant differences in age, race, sex, and BMI category between the groups (p < 0.01). Diabetes (33.5%) and hypertension (30.6%) were the most common primary causes of ESRD in patients with RA. Amyloidosis, vasculitis, and analgesic nephropathy combined accounted for less than 10% of cases of ESRD. Prednisone was the most commonly filled medication that could be used to treat RA (45.9% of RA patients). Hydroxychloroquine was the most frequently filled DMARD (13.5%); biologics were uncommon (etanercept 2.5%, adalimumab 1.5%; golimumab, infliximab, anakinra, and abatacept <1%). The co-occurrence of RA with ESRD was 1.1% in the USRDS by 2011. Physicians should be aware of the critical impact of the comorbidities of diabetes and hypertension in causing ESRD in RA patients. Use of DMARDS other than hydroxychloroquine and biologics to treat RA in the setting of ESRD appears to be infrequent. Further prospective studies of treatment strategies for RA in ESRD are needed.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Fractures in patients with rheumatoid arthritis and end-stage renal disease.
September 2020, Archives of osteoporosis,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Rheumatoid Arthritis and Mortality in End Stage Renal Disease.
March 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Amyloid Goiter in a Patient with Rheumatoid Arthritis and End-Stage Renal Disease.
January 2020, Indian journal of nephrology,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Frequency of gouty arthritis in patients with end-stage renal disease in Japan.
July 2005, Internal medicine (Tokyo, Japan),
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Differences in illness intrusiveness across rheumatoid arthritis, end-stage renal disease, and multiple sclerosis.
June 1993, The Journal of nervous and mental disease,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Renal ablation in patients with end-stage renal disease.
July 2011, VASA. Zeitschrift fur Gefasskrankheiten,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Anti-citrullinated protein antibody and rheumatoid factor in patients with end-stage renal disease.
January 2009, Clinical chemistry and laboratory medicine,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Helping patients with end-stage renal disease.
May 2007, The American journal of nursing,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
Cardiac disease in patients with end-stage renal disease.
May 1995, Cardiology clinics,
Sunita Paudyal, and Frances M Yang, and Christopher Rice, and Chen-Chun Chen, and Michael Skelton, and Monique Bethel, and Shilpa Brown, and Norris Stanley Nahman, and Laura Carbone
End-stage renal disease in patients with Fabry disease.
June 2002, Journal of the American Society of Nephrology : JASN,
Copied contents to your clipboard!